400-998-5282
专注多肽 服务科研

贝那鲁肽是一种重组人GLP-1(rhGLP-1),被批准为治疗糖尿病的新药。贝那鲁肽对肥胖也有很好的疗效。
编号:430912
CAS号:123475-27-4/107444-51-9
单字母:H2N-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-OH
| 参考文献(References): | G. Bell et al., Nature, 304, 368 (1983) |
贝那鲁肽是一种重组人GLP-1(rhGLP-1),被批准为治疗糖尿病的新药。贝那鲁肽对肥胖也有很好的疗效。
Beinaglutide is a recombinant human GLP-1 (rhGLP-1) approved as a novel drug for diabetes treatment. Beinaglutide also has promising effect on obesity.
GLP-1片段是从小肠下部分离出来的,目前被认为是最重要的肠促胰岛素激素。它显示出强烈的促胰岛素作用,这是由胰腺β细胞中表达的受体介导的。它被认为是非胰岛素依赖性(2型)糖尿病和相关神经病变的新型治疗策略。
The GLP-1 fragment is isolated from the lower small intestine and is presently regarded to be the most important incretin hormone. It shows a strong insulinotropic effect that is mediated by receptors expressed in the pancreatic beta-cells. It is proposed to be a novel therapeutic strategy for non-insulin-dependent (type 2) diabetes mellitus and associated neuropathy.





